STAT+: Prime wins Beam arbitration, clearing path to clinic

Article excerpt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A father fights to create and then save his daughter’s gene therapy, the White House nears a decision on an FDA chief, and the Trump administration pushes drugmakers to reshore generics manufacturing. A quest to save Grace, and help rare disease patients everywhere With $70 million and seemingly every fiber of his being, Matt Wilsey built a gene therapy company from scratch, recruiting Nobel laureates and biotech veterans to will an experimental treatment into existence for his daughter Grace. The treatment, for the ultra-rare disorder NGLY1 deficiency, landed her back in the hospital before she slowly began to recover, STAT’s Jason Mast and Matt Herper write. C